Format

Send to

Choose Destination
Transgenic Res. 2017 Oct;26(5):709-713. doi: 10.1007/s11248-017-0028-z. Epub 2017 Jul 20.

Fostering responsible research with genome editing technologies: a European perspective.

Author information

1
INSERM Ethics Committee, Paris, France. Herve.chneiweiss@inserm.fr.
2
INSERM Ethics Committee, Paris, France. francois.hirsch@inserm.fr.
3
National Centre for Biotechnology (CNB-CSIC), CSIC Ethics Committee and CIBERER-ISCIII, Madrid, Spain. montoliu@cnb.csic.es.
4
Institute of Medical Radiology and Cell Research, University of Würzburg, Wūrzburg, Germany.
5
INSERM Ethics Committee, Paris, France.
6
University Panthéon-Assas, Paris, France.
7
University of Geneva, Geneva, Switzerland.
8
Catholic University of Louvain, Louvain, Belgium.
9
National University of Ireland, Galway, Ireland.
10
Research Group on Law, Science, Technology and Society (LSTS), Vrije Universiteit Brussel, Ixelles, Belgium.
11
University of Malta, Msida, Malta.
12
Faculty of Biology, Institute of Genetics and Biotechnology, University of Warsaw, Warsaw, Poland.
13
University of Vienna, Vienna, Austria.
14
UNESCO Chair on Bioethics, Medical University of Vienna, Vienna, Austria.
15
German National Academy of Sciences Leopoldina, Halle, Germany.
16
Instituto de Bioética, and Portuguese National Council for Ethics in Life Sciences, Universidade Católica Portuguesa, Porto, Portugal.
17
European Research Ethics Committee Network (EUREC), Ixelles, Belgium.
18
Head of Human Medicines Special Areas, European Medicines Agency, London, UK.

Abstract

In this consensus paper resulting from a meeting that involved representatives from more than 20 European partners, we recommend the foundation of an expert group (European Steering Committee) to assess the potential benefits and draw-backs of genome editing (off-targets, mosaicisms, etc.), and to design risk matrices and scenarios for a responsible use of this promising technology. In addition, this European steering committee will contribute in promoting an open debate on societal aspects prior to a translation into national and international legislation.

KEYWORDS:

CRISPR-Cas; Gene editing; Responsible research and innovation; Science and society

PMID:
28730514
PMCID:
PMC5601998
DOI:
10.1007/s11248-017-0028-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center